On the morning of December 16, WuXi Biologics announced on the Hong Kong Stock Exchange that it had learned that the company's shares had unusual fluctuations in stock price and trading volume on December 15. As at the date of this announcement, the Company is not aware of any changes in the regulatory regime that could materially adversely affect the operations of its business. The company will continue to work hard to empower its partners and be confident in continued high-speed growth ahead.
The Company acknowledges that it is not aware of any information required to be disclosed under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong). As a Contract Custom Manufacturing Services (CDMO) company that provides a full range of end-to-end solutions, the company helps global partners discover, develop and produce biologics for the benefit of patients. The Company would like to emphasize that the applicable laws and regulations are strictly observed at all operating bases around the world and that all business operations are normal.
In addition, WuXi Biologics announced that the Board of Directors has agreed to use the repurchase authorization to repurchase shares on the open market from time to time for a total price not exceeding US$500 million.
As of yesterday's close, WuXi Biologics plunged 19.24% to HK$79.100.
![The latest announcement of Baiao Intelligent: Shareholders intend to reduce their total holdings of not more than 3.38% of the company's shares[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)